Benitec Biopharma (BJ9) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bb-301: Dose Escalation Phase 1B Cohort 1, Bb-301: Dose Escalation Phase 1B Cohort 2, Bb-301: Dose Escalation Phase 1B Cohort 3, Bb-301: Dose Expansion Phase 2A | Oculopharyngeal Muscular Dystrophy | phase1AndPhase2 | Recruiting | A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia | Dec 15, 2023 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Bb-301: Dose Escalation Phase 1B Cohort 1, Bb-301: Dose Escalation Phase 1B Cohort 2, Bb-301: Dose Escalation Phase 1B Cohort 3, Bb-301: Dose Expansion Phase 2A | phase1AndPhase2 | Oculopharyngeal Muscular Dystrophy | Recruiting | A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia | Dec 15, 2023 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Benitec Biopharma (DE:BJ9) have in its pipeline
Benitec Biopharma DE:BJ9 is currently developing the following drugs: Bb-301: Dose Escalation Phase 1B Cohort 1, Bb-301: Dose Escalation Phase 1B Cohort 2, Bb-301: Dose Escalation Phase 1B Cohort 3, Bb-301: Dose Expansion Phase 2A. These drug candidates are in various stages of clinical development as the company works toward FDA approval.